US 12,391,644 B2
Potassium channel inhibitors
David Tristram Brown, Glostrup (DK); Palle Christophersen, Glostrup (DK); Thomas Amos Jacobsen, Glostrup (DK); Janus S. Larsen, Glostrup (DK); Pernille Hartveit Poulsen, Glostrup (DK); and Dorte Strøbaek, Glostrup (DK)
Assigned to Saniona A/S, Glostrup (DK)
Filed by Saniona A/S, Glostrup (DK)
Filed on May 2, 2024, as Appl. No. 18/652,849.
Application 18/652,849 is a division of application No. 17/437,447, granted, now 12,006,289, previously published as PCT/EP2020/057816, filed on Mar. 20, 2020.
Claims priority of application No. 19164637 (EP), filed on Mar. 22, 2019.
Prior Publication US 2024/0368077 A1, Nov. 7, 2024
Int. Cl. C07D 205/04 (2006.01); C07C 211/40 (2006.01); C07C 233/62 (2006.01); C07C 271/24 (2006.01); C07C 311/07 (2006.01); C07D 207/09 (2006.01); C07D 213/61 (2006.01); C07D 265/30 (2006.01)
CPC C07D 205/04 (2013.01) [C07C 211/40 (2013.01); C07C 233/62 (2013.01); C07C 271/24 (2013.01); C07C 311/07 (2013.01); C07D 207/09 (2013.01); C07D 213/61 (2013.01); C07D 265/30 (2013.01)] 19 Claims
 
1. A method for treating inflammatory bowel disease (IBD), hereditary xerocytosis, acute respiratory distress syndrome (ARDS), or a combination thereof, in a subject in need thereof, comprising administering to the subject a compound of any of the following formulae:

OG Complex Work Unit Chemistry
wherein:
R14 is selected from the group consisting of —C(O)—C1-8 linear or branched alkyl optionally substituted with cyclopropyl; —C(O)—O—C1-8 linear or branched alkyl optionally substituted with cyclopropyl; —C2-8 linear or branched alkyl optionally substituted with —OH; —H and —S(O)2—C1-8 linear or branched alkyl;
R3 is H or C1-5 linear or branched alkyl;
R4 is H, C1-5 linear or branched alkyl;
R6 is H or C1-5 linear or branched alkyl;
R8 is selected from the group consisting of H, C1-5 linear or branched alkyl, and —C(O)—O—C1-8 linear or branched alkyl;
A is a phenyl or a pyridinyl, wherein the phenyl or pyridinyl is optionally substituted with one or more substituents R13 individually selected from the group consisting of halogen, —CX3, —OCX3, —CHX2, —OCHX2, —CH2CX3, and OCH2CX3; and
X is halogen;
or a pharmaceutically acceptable salt thereof.